Philipp D. Le Coutre
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications
Correction: Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97).
Journal: Frontiers in oncology
Published: March 23, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
Journal: Leukemia
Published: March 05, 2026
Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97).
Journal: Frontiers in oncology
Published: February 02, 2026
Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Journal: Haematologica
Published: October 31, 2025
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Journal: Leukemia
Published: October 28, 2025
Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML.
Journal: Frontiers in oncology
Published: September 23, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.
Journal: Leukemia
Published: February 21, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
Journal: Leukemia
Published: February 14, 2025
Last Updated: 09/26/2026